Antithrombin III and Heparin Inactivation in Thrombin Involving Reactions

Summary

The inhibitory capacity of antithrombin III (AT III) was measured by a quantitative method independent of the velocity of inhibition. When AT III was in excess of thrombin in plasma or in purified system the capacity of inhibitor decreased quantitatively in proportion to the amount of thrombin neutralized. Heparin present in reaction together with thrombin invariably induced a more extensive utilization of inhibitor than thrombin alone. The extent of this additional loss of inhibitory capacity was to a limited degree related to the concentration of heparin. Heparin itself was neutralized in thrombin-AT III reaction losing its anticoagulant property in proportion to the amount of thrombin bound by inhibitor. This quantitative neutralization of heparin occurred not only when the anticoagulant participated in thrombin-AT III binding but also when heparin was added to a medium containing a preformed thrombin-AT III complex. These results suggest that acceleration of binding and increased utilization of binding capacity are the two regular effects of heparin on thrombin-involving reactions of AT III. Both of these effects may be abolished by quantitative binding of heparin to thrombin-AT III complex.

• References

• 1 Abildgaard U. 1969; Binding of thrombin to antithrombin III. Scandinavian Journal of Clinical and Laboratory Investigation 24: 23.
• 2 Briginshaw G. F, Shanberge J. N. 1974; Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X. Thrombosis Research 4: 463.
• 3 Gitel S. N, Wessler S. 1975; Plasma antithrombin III: a quantitative assay of biological activity. Thrombosis Research 7: 5.
• 4 Heimburger N, Haupt H, Schwick H. G. 1971; Proteinase inhibitors of human plasma. Proceedings of the International Research Conference on Proteinase Inhibitors, Munich 1970: 1.
• 5 Hirsh J, van Aken W. G, Gallus A. S, Dollery C. T, Cade J. F, Yung W. L. 1976; Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53: 691.
• 6 Kurachi K, Fujikawa K, Schmer G, Davie E. 1976; Inhibition of bovine factor IXa and factor Xa by antithrombin III. Biochemistry 15: 373.
• 7 Machovich R. 1975; a Heparin-sensitive and nonsensitive forms of thrombin. Biochimica et Biophysica Acta 400: 62.
• 8 Machovich R. 1975; b Mechanism of action of heparin through thrombin on blood coagulation. Biochimica et Biophysica Acta 412: 13.
• 9 Machovich R, Blasko G, Aranyi P. 1975; The interaction of thrombin and heparin. Heat inactivation kinetics. Thrombosis Research 7: 253.
• 10 Marciniak E. 1973; Factor Xa inactivation by antithrombin III: evidence for biological stabilization of factor Xa by factor V-phospholipid complex. British Journal of Haematology 24: 391.
• 11 Marciniak E. 1974; Binding of heparin in vitro and in vivo to plasma proteins. Journal of Laboratory and Clinical Medicine 84: 344.
• 12 Marciniak E. 1975; Adverse effect of heparin in thrombin-antithrombin III interaction. Thrombosis et Diathesis Haemorrhagica 34: 748.
• 13 Portmann F, Holden W. D. 1949; Protamine (salmine) sulfate, heparin, and blood coagulation. Journal of Clinical Investigation 28: 1951.
• 14 Rosenberg R. D, Damus P. S. 1973; The purification and mechanism of action of human antithrombin-heparin cofactor. Journal of Biological Chemistry 248: 6490.
• 15 Seegers W. H, McCoy L, Kipfer R. K, Murano G. 1968; Preparation and properties of thrombin. Archives of Biochemistry and Biophysics 128: 194.
• 16 Tschesche H, Klein H. 1968; Modifizierung und Hemmverhalten des spezifischen Trypsininhibiters aus Schweinpankreas – eine im sauren katalysierbare tryptische Hydrolyse. Zeitschrift für Physiologische Chemie 349: 1645.
• 17 van Crevels S, Paulssen M. M. P. 1951; Significance of clotting factor in blood-platelets, in normal and pathological conditions. Lancet 2: 242.